Treating type 2 diabetes in youth:a depressing picture by Pearson, E R
228
cl
in
ica
l
Clinical opinion
Treating type 2 diabetes in youth: a depressing 
picture
ER Pearson 
Clinical Reader, Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Scotland, UK
Correspondence to ER Pearson
Medical Research Institute, 
University of Dundee, 
Nethergate, Dundee DD1 4HN
Scotland, UK
tel. +44 (0)1382 383387
e-mail e.z.pearson@dundee.ac.uk
J R Coll Physicians Edinb 2012; 42:228
http://dx.doi.org/10.4997/JRCPE.2012.309
© 2012 Royal College of Physicians of Edinburgh
TiTle A clinical trial to maintain glycemic control in youth with type 2 diabetes.
AuThors Zeitler P, Hirst K, Pyle L et al. 
JournAl New Engl J Med 2012; 366:2247–56. http://dx.doi.org/10.1056/
NEJMoa1109333
DeclArATion of inTeresTs No conflicts of interest declared.
summAry
There is an increase in type 2 diabetes (T2D) in children, 
yet little evidence to guide management. The TODAY 
study aimed to assess the impact of three treatment 
interventions in this demographic group.1 In this study 927 
children were converted from their current medication 
to metformin monotherapy. This run-in phase proceeded 
to randomisation if an HbA1c <8% (64 millimoles per 
mole [mmol/mol]) was achieved with adherence to 
medication >80% for at least six weeks. The randomisation 
cohort consisted of 699 children, aged between 10 and 
17 years with T2D diagnosed within the past two years 
and a body mass index (BMI) >85th percentile. The 
ethnicity split was 41% Hispanic, 31.5% non-Hispanic 
Black, and 20% non-Hispanic White. The children were 
randomly assigned to stay on metformin alone, to have 
rosiglitazone added to their regime, or to continue on 
metformin and undergo a family based behavioural weight 
loss programme. This consisted of weekly visits for the 
first six months, then biweekly for six months, then 
bimonthly for the remainder of the study. The primary 
endpoint was either an HbA1c >8% for more than six 
months, or sustained insulin treatment for more than 
three months.
Treatment failure was observed in 45.6% of children; 50% 
by 11.5 months after randomisation.  Treatment failure 
was seen less in those with rosiglitazone added (38.6%) 
compared to those who stayed on metformin alone 
(51.7%, p=0.006). Intensive lifestyle intervention had an 
intermediate result (46.6% failure) but this did not differ 
significantly from those taking metformin alone. The 
authors conclude that whatever the intervention, 
progression of diabetes is rapid in this age group and that 
multiple oral treatments or insulin will be required within 
a few years for the majority of this group.
opinion 
With the increase in obesity rates in children, there is 
increasing prevalence of T2D in young people. While still 
relatively uncommon in the UK, in some ethnic groups 
in the US the incidence of T2D in children aged over 10 
years old exceeds that of type 1 diabetes.2 These 
children present a major challenge to healthcare systems 
due to the long duration of diabetes and other 
co-morbidities related to their obesity and insulin 
resistance. The TODAY study was a valiant attempt to 
develop an evidence base for management of this 
problematic group.
This was a challenging study to undertake due to the 
characteristics of children who develop T2D. This is 
highlighted by some striking figures – during the study 
period 19.2% of the children had a serious adverse event, 
which was mostly due to hospitalisation; 41.5% of the 
participants had a household income <US$25,000 and 
61% did not live with both their parents.3 The TODAY 
study group spent considerable effort in engaging with this 
group, yet adherence to treatment was just 57% by month 
60, and only 54% of participants randomised to lifestyle 
intervention attended for more than 75% of visits.1
The results overall present a depressing picture. Roughly 
half of the children required additional treatment, half of 
these within one year. Despite what is clearly a disease 
driven by obesity, intensive lifestyle intervention – much 
more intensive than can be achieved in clinical practice – 
did not alter progression rates of diabetes or other 
parameters such as blood pressure or cholesterol level. 
The only effective intervention was to add more 
pharmacological therapy, and even here the progression 
rates remained high. The solution, of course, is for children 
to avoid ‘diabesity’ in the first place – easier said than done.
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